Hemab Therapeutics, a biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombosis disorders, unveiled its lead candidate, HMB-001, a novel bispecific antibody...
Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the...
Global biotherapeutics leader CSL Behring announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus...
BioMarin Pharmaceutical Inc. announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety...
